kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CEACAM8 /CD66b Protein, 100µg  

Recombinant human CEACAM8 /CD66b Protein, 100µg

Recombinant Human CEACAM8 /CD66b Protein (rhCEACAM8) Gln35-Ser319 was produced in human 293 cells (HEK293).

Synonym: recombinant, human, protein CEACAM8, CD66b, CD67, CGM6

More details


Availability: within 7 days

378,00 €

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.[1-4]

Recombinant Human CEACAM8 /CD66b Protein (rhCEACAM8) Gln35-Ser319 (Accession # NP_001807.2)was produced in human 293 cells (HEK293).

Molecular Characterization
rhCEACAM8, fused with 6×his tag at C-terminus and has a calculated MW of 33 kDa expressed. The predicted N-terminus is Gln35. Protein migrates as 48-65 kDa in reduced SDS-PAGE resulting from glycosylation.

Less than 1.0 EU per μg of the rhCEACAM8 by the LAL method.

>95% as determined by SDS-PAGE.

Refer to data sheet

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C). 


(1) Oikawa,S. et al., 2000, Biochem Biophys Res Commun  278 (3):564-8.
(2) Lasa,A. et al., 2008, Ann Hematol  87 (3):205-11.
(3) Ramachandran P, et al., 2006, J. Proteome Res. 5 (6): 1493–503.
(4) Zhao L, et al., 2002, J. Immunol. Methods 270 (1): 27–35.